Dose-dependent efficacy of olezarsen in high-risk hypertriglyceridemia: A meta-analysis

doi:10.4330/wjc.121611

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 7

This Article

(19)

(21)

(0)

(217)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Cardiol. Jul 26, 2026; 18(7): 121611
Published online Jul 26, 2026. doi: 10.4330/wjc.121611

Table 2 Tabulated representation of baseline characteristic of included population, mean ± SD/n (%)/median (IQR)

Characteristics		Balance trial 2024		Bridge-TIMI 73a 2024		Essence-TIMI 2025
Characteristics		Olezarsen 50 mg	Olezarsen 80 mg	Olezarsen 50 mg	Olezarsen 80 mg	Olezarsen 50 mg	Olezarsen 80 mg
Age (year)		43.2 ± 12.1	47.7 ± 13.3	63 (54-71)	60 (54-69)	63 (57-69)	64 (56-70)
Female		6 (29)	11 (50)	24 (41)	24 (62)	97 (38.2)	306 (39.9)
Race	White	17 (81)	17 (77)	54 (93)	52 (91)	240 (94.5)	713 (93.1)
	Black	0	2 (9)	3 (5)	5 (9)	2 (0.8)	34 (4.4)
	Hispanic or Latino	3 (14)	1 (5)	21 (36)	23 (40)	67 (26.4)	179 (23.4)
	Asian	3 (14)	3 (14)	1 (2)	0	6 (2.4)	8 (1.0)
BMI (kg/m²)		22.4 ± 3.5	25.1 ± 6.0	32.9	33.0	31.6 (28.3-34.9)	31.5 (28.5-35.9)
DM		3 (14)	7 (32)	37 (64)	30 (77)	151 (59.4)	468 (61.1)
Pancreatitis		15 (71)	17 (77)	2 (3)	0 (0)	-	-
Lipid panel (mg/dL)	ApoC-III	27.7 ± 10.5	27.5 ± 11.6	15.3 (12.0-19.3)	15.8 (13.2-18.7)	15.2 (12.3-18.8)	15.3 (12.9-18.3)
	Triglyceride	2684 ± 1235	2613 ± 1499	230.0 (182.5-331.5)	241.5 (179.5-357.5)	235.3 (186.5-309.5)	237.3 (191.5-306.0)
	LDL cholesterol	17.6 ± 8.5	22.8 ± 14.1	83.8 (59.5-106.0)	81.5 (62.0-104.5)	79.0 (58.0-112.0)	81.0 (60.0-107.3)
	Apolipoprotein B	65.2 ± 13.5	58.4 ± 7.2	90.8 (75.5-105.0)	94.0 (78.0-114.5)	89.5 (73.1-110.3)	90.7 (74.0-109.0)
	Non-HDL cholesterol	307.6 ± 101.8	262.9 ± 100.4	132.2 (103.5-156.5)	134.5 (110.0-161.5)	123.3 (97.5-158.0)	126.0 (99.5-155.5)

BMI: Body mass index; DM: Diabetes mellitus; ApoC-III: Apolipoprotein C-III; LDL: Low density lipoproteins; HDL: High-density lipoproteins.

Full Size Table

Citation: Patel V, Sohail R, Alam M, Chaudhry S, Mehdi S, Patel S, Patel R, Khattak R, Khan Z, Patel M. Dose-dependent efficacy of olezarsen in high-risk hypertriglyceridemia: A meta-analysis. World J Cardiol 2026; 18(7): 121611
URL: https://www.wjgnet.com/1949-8462/full/v18/i7/121611.htm
DOI: https://dx.doi.org/10.4330/wjc.121611

Patel V, Sohail R, Alam M, Chaudhry S, Mehdi S, Patel S, Patel R, Khattak R, Khan Z, Patel M. Dose-dependent efficacy of olezarsen in high-risk hypertriglyceridemia: A meta-analysis. World J Cardiol 2026; 18(7): 121611 [DOI: 10.4330/wjc.121611]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.